Title: Clinical observation of valsartan combined with hydrochlorothiazide or amlodipine in hypertension with left ventricular hypertrophy
Abstract: Objective To compare the effect of valsartan combined with hydrochlorothiazide or amlodipine in hypertension with left ventricular hypertrophy(LVH).Methods 242 cases patients with hypertension with LVH were Randomly divided into amlodipine group(n=122) and hydrochlorothiazide group(n=120).Hydrochlorothiazide group received valsartan 80~160mg/d and hydrochlorothiazide 12.5~25mg/d,and amlodipine group received valsartan 80~160mg/d and amlodipine 2.5~10mg/d.Recorded the end-diastolic interventricular septum thickness(IVST),left ventricular end-diastolic diameter(LVDD),end-diastolic left ventricular posterior wall thickness(LVPWT) when the patients were chosen into the test and after two years follow-up,and recorded the adverse reaction and cardiovascular event in the follow-up period.Results After 2 years,the level of IVST,LVDD and LVPT of two groups were better than those of before test,the difference were statistically significant(P0.05);But the difference between two groups was no statistically significant(P0.05).The incidence rate of gastrointestinal reaction and total adverse reaction of amlodipine group were lower than those of hydrochlorothiazide group,the difference were statistically significant(P0.05).The incidence rate of heart failure,serious arrhythmias and overall incidence of cardiovascular event of hydrochlorothiazide group were lower than those of amlodipine group,the difference were statistically significant(P0.05).Conclusion The clinical effect of valsartan combined with hydrochlorothiazide or amlodipine in hypertension with left ventricular hypertrophy is similar,but the valsartan combined amlodipine can reduce the incidence rate of cardiovascular event,less adverse reaction,prognosis better,and the patients can get more benefit.
Publication Year: 2011
Publication Date: 2011-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot